Compare Bill.com Holdings Inc (BILL) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bill.com Holdings Inc vs Merck & Co., Inc. — how do they compare? Bill.com Holdings Inc trades at $44.29 (market cap $4.12B), while Merck & Co., Inc. trades at $123.66 (market cap $298.31B). The key difference: Merck & Co., Inc. is far larger — about 72.4× Bill.com Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.82% dividend while Bill.com Holdings Inc pays none. Which is the better fit depends on your goals.
| BILL | MRK | |
|---|---|---|
Market Cap | $4.12B | $298.31B |
Sector | Technology | Health |
52-Week High | $56.32 | $129.52 |
52-Week Low | $31.96 | $77.60 |
Enterprise Value | $3.83B | $341.72B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BILL Holdings trades at $42.86, up 3.63% today, with strong technical momentum and bullish analyst sentiment. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $0.68 surpassing the $0.55 estimate. Revenue growth is robust, rising from $642M in 2022 to $1.46B in 2025, though net margins remain thin at 0.01%. Recent leadership changes and a $1B buyback program signal strategic focus on growth and shareholder value.
Outlook is positive with a consensus price target of $48.00 implying 12% upside, supported by 56% analyst buy ratings. Key risks include high valuation multiples (P/E 213.91), competitive pressures in SaaS, and sensitivity to small business economic health. Cash flow trends show operational improvement, but investing outflows remain elevated.
Merck (MRK) trades at $123.45, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, including Q1 2026, and the company is actively expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Revenue reached $65.01B in 2025 with a net income margin of 28.07%, though 2026 forecasts show a decline in profitability.
The outlook remains positive with a consensus price target of $137.30, offering ~11% upside. Key risks include increased debt levels, competitive pressures in oncology, and potential regulatory hurdles from acquisitions. Institutional buying activity supports confidence, but investors should monitor execution on growth initiatives and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
